---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-121749"
form_type: "8-K"
ticker: "TRAW"
cik: "0001130598"
company_name: "Traws Pharma, Inc."
filed_at: "2025-12-17T23:59:59+00:00"
generated_at: "2026-05-16T12:52:03.807044+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Traws Pharma ratutrelvir shows fewer adverse events and no viral rebound in interim Phase 2 COVID-19 data vs PAXLOVID

## Summary
- Interim analysis of 37 patients: 25 on ratutrelvir 600 mg once daily 10 days, 12 on PAXLOVID 5-day regimen.
- No viral rebound observed in ratutrelvir arm; 1 rebound (8.3%) in PAXLOVID arm.
- 24% of ratutrelvir cohort were PAXLOVID-ineligible; symptom improvement consistent with broader group.
- Adverse events lower: 7.6% mild dyspepsia on ratutrelvir vs 30% dysgeusia/dizziness/dyspepsia on PAXLOVID.
- Final data expected January 2026; enrollment >50% of planned 90-patient study.

## SEC filing metadata
- accession: 0001104659-25-121749
- form_type: 8-K
- ticker: TRAW
- cik: 0001130598
- company_name: Traws Pharma, Inc.
- filed_at: 2025-12-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130598/000110465925121749/0001104659-25-121749-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130598/000110465925121749/tm2533729d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-121749
- JSON: https://secwatch.observer/filing/0001104659-25-121749.json
- Plain text: https://secwatch.observer/filing/0001104659-25-121749.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.